Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 07, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,534.65 pence per share.
- Treasury Holdings: 177,801,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,806,453,039 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 500,000 shares on July 07, 2006. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the 500,000 share repurchase based on the disclosed price of 1,534.65 pence per share.
- Confirm the updated total share count (5,806,453,039 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authorization.